Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report

Area of Science:

• Gastroenterology
• Immunology
• Nutritional Science

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease requiring effective therapeutic strategies.
• Current treatments for mild to moderate UC may have limitations, necessitating novel approaches.
• Vitamin E, specifically d-alpha tocopherol, possesses antioxidant and anti-inflammatory properties that may benefit UC management.

Purpose of the Study:

• To evaluate the efficacy of rectal d-alpha tocopherol in managing mild to moderately active ulcerative colitis.
• To investigate the potential antioxidant and anti-neutrophil recruitment effects of this intervention.

Main Methods:

• An open-label study involving 15 patients with mild to moderate UC.
• Rectal d-alpha tocopherol enema (8000 U/day) administered for 12 weeks.
• Disease activity assessed using the Mayo disease activity index (DAI), with endoscopic evaluations at baseline, week 4, and week 12.

Main Results:

• Significant reduction in average DAI scores from 8 to 2.3 after 12 weeks (P < 0.0001).
• Clinical response observed in all 14 evaluable patients by week 12.
• Remission achieved in 64% (9 out of 14) of patients after 12 weeks of therapy.
• No adverse events or hospitalizations due to disease exacerbation were reported.

Conclusions:

• Rectal d-alpha tocopherol demonstrates potential as a novel therapeutic option for mild to moderate UC.
• The anti-inflammatory and antioxidant properties of vitamin E likely contribute to the observed therapeutic benefits.
• Further research is warranted to confirm these preliminary findings and elucidate the precise mechanisms of action.